REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

13 Jan 2025 05:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

10 Jan 2025 11:29:29 By NetDania Notify

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

07 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 Dec 2024 08:45:02 By NetDania Notify

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

19 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 Dec 2024 14:08:04 By NetDania Notify

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

17 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

17 Dec 2024 08:45:01 By NetDania Notify

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

17 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

16 Dec 2024 15:30:25 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 Dec 2024 08:45:56 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Dec 2024 08:46:56 By NetDania Notify

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

09 Dec 2024 16:45:23 By Nasdaq GlobeNewswire

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

07 Dec 2024 18:00:31 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

21 Nov 2024 09:19:05 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

20 Nov 2024 08:58:38 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 Nov 2024 09:06:22 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 Nov 2024 08:45:40 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 Nov 2024 08:45:06 By NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

14 Nov 2024 23:59:51 By Nasdaq GlobeNewswire